Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 2
- 主要终点
- Number of Participants With Reduction in Ventricular Tachycardia (VT) Burden
研究概览
简要总结
Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation (ENCORE) for Treatment of Ventricular Tachycardia
详细描述
Patients with Ventricular Tachycardia (VT) who have failed standard therapy (medicines, invasive catheter ablation) have limited options, with one-year survival below 20%. Preclinical data demonstrate that single fraction stereotactic body radiotherapy (SBRT) to discrete portions of the heart is feasible and may result in a reduction or elimination of VT. The efficacy may be further improved when guided by cardiac electrophysiologic (EP) testing. In total, the mapping and ablation proposed for this EP-guided Noninvasive Cardiac Radioablation (ENCORE) is a rapid and totally non-invasive method. Overall safety and early efficacy of ENCORE have not been rigorously studied in a prospective trial to-date. The purpose of this phase I/II study is to demonstrate the short-term safety and preliminary efficacy of ENCORE for patients with life-threatening, treatment-refractory VT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DOCUMENTED VT:
- •Patient must have documented sustained monomorphic ventricular tachycardia as documented on either a 12-lead ECG or intracardiac ICD interrogation
- •Monomorphic PVCs documented on a 12-lead ECG.
- •ANTIARRHYTHMIC MEDICATION: Patient must have failed or become intolerant to at least one antiarrhythmic medication (amiodarone, sotalol, or mexiletine).
- •CATHETER ABLATION: Patient must have failed at least one invasive catheter ablation procedure, or have a contraindication to a catheter ablation procedure (e.g., LV thrombus, severe pulmonary disease), or have VT thought to arise from a protected location (e.g., epicardial VT with history of previous cardiac surgery).
- •MINIMUM VT BURDEN: Patient must have either:
- •At least 3 VT episodes (sustained VT, ICD ATP or ICD shock) over previous 6 months prior to enrollment -OR-
- •>20% PVC burden with a cardiomyopathy (LVEF<50%)
- •Patient must be deemed medically fit for stereotactic body radiation therapy by the treating physician.
- •Patient must be > 18 years old.
- •Patient must be able to understand and be willing to sign an IRB approved written informed consent document.
排除标准
- •Patient must not have past history of radiotherapy within the projected treatment field.
- •Advanced symptomatic heart failure as defined as NYHA Class IV heart failure (inotrope dependent and/or current left-ventricular assist device (LVAD))
- •Polymorphic VT or ventricular fibrillation (VF) as a clinical heart rhythm (as determined by 12-lead ECG and/or ICD interrogation).
- •More than 3 distinct clinical VT morphologies observed (ECG or ICD interrogation or invasive EP study) OR more than 5 distinct induced VT morphologies during ECGI testing.
- •Advanced myocardial scar substrate that would require stereotactic delivery to a target volume deemed unsafe by the treating physician.
- •Unlikely to live 12 months, in the absence of VT, as best based on clinical judgment by the treating and enrolling physicians.
- •Patient must not be pregnant and/or breastfeeding and must have a negative pregnancy test within 14 days of study entry.
结局指标
主要结局
Number of Participants With Reduction in Ventricular Tachycardia (VT) Burden
时间窗: 12 months (6mo prior to and 6mo post SBRT)
Primary efficacy endpoint is defined by the number of subjects with a reduction in VT burden comparing the period six months before ENCORE treatment to the six months after ENCORE treatment as adjudicated by continuous ICD monitoring (number of ATP and ICD shocks and sustained (\>30 second) nontreated slow VT). There will be a six-week "blanking period" after therapy to allow for ablation effect. For patients with PVC-induced cardiomyopathy, the primary efficacy will be any reduction in PVC burden based on ambulatory heart monitors.
Number of Serious Adverse Events
时间窗: < or = 90 days
Demonstrate acute (≤ 90 days) safety of noninvasive stereotactic cardiac ablation radiotherapy (ENCORE). The primary safety endpoint is defined by a ≤ 20% rate of serious adverse events (SAEs) using CTCAE v4.0 criteria that are possibly/probably/definitely related to study treatment, based on previously published data for expected invasive catheter-based VT-ablation procedures.
次要结局
- Number of Adverse Events That Are Possibly/Probably/Definitely Related to Study Treatment(90 days to 12 months)
- Number of Participants With a 50% Reduction in Ventricular Tachycardia (VT) Burden(6 months)
- Number of Participants With Reduction in ICD Shocks and LVEF Improvement(6 months)
- Number of Participants With Reduction in Ventricular Tachycardia (VT) Therapies Between 6 and 12 Months(12 months)
- Number of Participants With a 95% Reduction in Ventricular Tachycardia (VT) Burden(6 months)
- Overall Survival(12 months)
- Health Related Quality of Life (HRQOL)(6 week, 6 month, 12 month)
研究者
Phillip Cuculich
M.D.
Washington University School of Medicine